Member Info for Cashintime

I think we will see the expansion of Polb 001 into many uses and this oncology associated use is one of the most important of them. The presentation tonight will give us a planned pathway for 2023.

I can see Pfizer take an interest in our AI collaboration with Cytoreason as they have 100m invested with them in their own AI study where they ended up taking a stake in Cytoreason as part of the deal.
Our data bank from Hvivo is unique and will be sought after in the industry.
It is partnership now that will drive this company forward and I have no doubt we have set the groundwork for such.

All buys this afternoon, FOMO, as they say in the maternity ward, one last push will get us there.
That is back to the IPO price. So much has been achieved since then in a flawless carry out of the business madel with products added to the stable , IP protection and worldwide patents, GMP batches made, data, LPS studies, government approved grant aid and many top notch names brought aboard Poolbeg to add to the already excellent team. The capital light approach has been maintained. We are in the up cycle stage of the life of this company which has the ability to achieve 1 billion value and that is not a pie in the sky figure after Cathal Friels Amyrt success this week with the company he co founded bought for 1.4B. Looking forward to the presentation Monday to bring us all up to speed and give us an insight into what 2023 will look like for us.
Nasdaq listing news Monday too after press announcement this week of a planned IPO by year's end.

Price holding firm. Any new news discussion at Mondays presentation will give us a red dot first thing Monday morning.
The groundwork will be done for a partnership at JP Morgan where meetings were set up. It will take a while of course for a deal to be formally signed. I don't know how quick these things move. If the product appears to be the success that we have been told by RNS it has ,then it may have been ponched on

Any potential partner would be aware of this product since early last year and could well have been waiting on the sidelines for an indication of the LPS study results which we have early indication in hand now. They would have the resources to fast track the scan of more detailed data that is going to take until Q2 to get the final readout.
I think we will see American grant funding for Polb 003 soon enough and IP will be sought for products that the one three collaboration has identified
Big pharma in San Francisco will be very interested in our data with Pfizer after buying into Cytoreason as a stakeholder in part of their 100m AI deal with our Israeli friends.

I was thinking we were going to take on "a fallen angel" to carry out a reverse take over in order to get our Nasdaq listing.
Can anybody shed any light into what an IPO will do to current investors in terms of dilution etc. Is it in effect returning to the markets for capital which is what they said that they were not going to do . Would our shares be carried in on a one to one basis or as a ratio of the agreed IPO price at the time.
Cathal has plenty of skin in the game here and never takes his stake off the table. He is in for the big exit at the end. We can rest assured that our interests will be aligned with his own I'm sure.
I would have expected an RNS this morning when the IPO plan with advisors actively working on it was announced in the press.
We will find out more on Monday in the questions and answers I'm sure.

Reported on Newstalk this morning also. Double digits today

That's exactly it. Ones normal trading working day over there would start 2.30pm our time. Those interested on what is going on over here probably will buy in the OTC rather than LSE.

Is the afternoon buys coming from across the pond as their markets open 2.30pm GMT

Looks possible to get back to double digits today. Will we push on through is yet to be seen. Jeremy in San Francisco doing the groundwork for partnership. We are not hanging around like most AIM darlings.

That trade is outside the spread at the claimed time of trade. It has to have been worked through out the day. I believe it to be a buy otherwise it would be marked as a sell as it was below the mid price at the time.
This RNS had to have been passed by the nomad as fact
It is quiet clear that the LPS study has been a success. There should be momentum in the shareprice for the rest of the week as we run up to the 16th where we will get more details I'm sure. This year will be groundbreaking for this excellent run company.
This result could well be transformational for the company and will swing any potential Nasdaq reverse in the waiting. News incoming on our AI products soon also.

That's the vox markets link with Justin. Jeremy is very positive.
We should have lifted at least to 13p today for starters. We could attract JP Morgan client investors from across the pond in the next couple of days.

https://www.**********.co.uk/media/63bbcb5afa69cdba665326cc/

Great update, something positive to bring to San Francisco

https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.independent.ie/business/irish/dublin-rare-disease-treatment-specialist-amryt-in-14bn-sale-42271042.html&ved=2ahUKEwjj56Hb_rj8AhXEhFwKHRlWAe8QxfQBKAB6BAgFEAI&usg=AOvVaw3bxEM0mebuf2xWkbKdorwn

The 41st Annual Healthcare Conference will take place on January 9-12, 2023 in San Francisco, CA.

This premier conference is the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

Monday for the JP Morgan conference where deals are made. It is an annual event held in San Francisco where all the top tier of the industry meet. It will put Poolbeg in the spotlight.

I can smell an RNS coming tomorrow probably concerning the JP Morgan USA gig. Maybe with a little sweetener as well.
It is always a sea of blue as MMs raise the price and it definitely encourages buys. Dropping the price always seems to make the activity here stagnant. Doc has been constantly singing POLBs praises. I think he sees the value in the model here . Remember we have a good wedge of cash with no danger of a raise for years. We all hope we will be self funding by then. Maybe the darlings of AIM for 2023 are coming to the top. I genuinely can see a multi bag from these levels and rightly so.
My average is a bit over 6p so happy to be back in profit.

Nice 17.81k buy this morning @ 6.2p

Last time we passed 10p just before Christmas there was more buys than sells and they dropped us quickly in a matter of a couple of days on small volume. They would have created more of a market if they took the reigns off a little. It doesn't seem as they want the shareprice to be above that of our spun out of company. Can they not sever the cord and leave us rightfully stand on our own two feet.